OtherClinical Investigations (Human)
177Lu-3BP-227 for neurotensin receptor 1-targeted therapy of metastatic pancreatic adenocarcinoma – first clinical results
Richard P. Baum, Aviral Singh, Christiane Schuchardt, HARSHAD RAJARAM KULKARNI, Ingo Klette, Stefan Wiessalla, Frank Osterkamp, Ulrich Reineke and Christiane Smerling
Journal of Nuclear Medicine October 2017, jnumed.117.193847; DOI: https://doi.org/10.2967/jnumed.117.193847
Richard P. Baum
1 Zentralklink Bad Berka, Germany;
Aviral Singh
2 Zentralklinik Bad Berka, Germany;
Christiane Schuchardt
1 Zentralklink Bad Berka, Germany;
HARSHAD RAJARAM KULKARNI
1 Zentralklink Bad Berka, Germany;
Ingo Klette
2 Zentralklinik Bad Berka, Germany;
Stefan Wiessalla
2 Zentralklinik Bad Berka, Germany;
Frank Osterkamp
3 3B Pharmaceuticals GmbH, Germany
Ulrich Reineke
3 3B Pharmaceuticals GmbH, Germany
Christiane Smerling
3 3B Pharmaceuticals GmbH, Germany

Article Figures & Data
Additional Files
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 66, Issue 5
May 1, 2025
177Lu-3BP-227 for neurotensin receptor 1-targeted therapy of metastatic pancreatic adenocarcinoma – first clinical results
Richard P. Baum, Aviral Singh, Christiane Schuchardt, HARSHAD RAJARAM KULKARNI, Ingo Klette, Stefan Wiessalla, Frank Osterkamp, Ulrich Reineke, Christiane Smerling
Journal of Nuclear Medicine Oct 2017, jnumed.117.193847; DOI: 10.2967/jnumed.117.193847
177Lu-3BP-227 for neurotensin receptor 1-targeted therapy of metastatic pancreatic adenocarcinoma – first clinical results
Richard P. Baum, Aviral Singh, Christiane Schuchardt, HARSHAD RAJARAM KULKARNI, Ingo Klette, Stefan Wiessalla, Frank Osterkamp, Ulrich Reineke, Christiane Smerling
Journal of Nuclear Medicine Oct 2017, jnumed.117.193847; DOI: 10.2967/jnumed.117.193847
Jump to section
Related Articles
Cited By...
- Synthesis of 64Cu-, 55Co-, and 68Ga-Labeled Radiopharmaceuticals Targeting Neurotensin Receptor-1 for Theranostics: Adjusting In Vivo Distribution Using Multiamine Macrocycles
- Complexes of the neurotensin receptor 1 with small-molecule ligands reveal structural determinants of full, partial, and inverse agonism
- Theranostics: Leveraging Molecular Imaging and Therapy to Impact Patient Management and Secure the Future of Nuclear Medicine
- Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine
- Fibroblast-Activating Protein: Targeting the Roots of the Tumor Microenvironment